Results 221 to 230 of about 158,415 (307)

ZMAT1 Promotes Osteoclastogenesis Through TRIM46 Mediated YAP1 Degradation and Inhibits Osteoblastogenesis

open access: yesAdvanced Science, EarlyView.
Zmat1 deficiency mitigates pathological bone loss by impairing osteoclastogenesis and promoting osteoblastogenesis. Mechanistically, in osteoclasts, Zmat1 loss relieves transcriptional repression of the E3 ligase TRIM46, promoting YAP1 degradation and inhibiting osteoclastogenic genes.
Xinyu Chang   +13 more
wiley   +1 more source

Estrogens drive myeloid-derived suppressor cell accumulation

open access: yesOncoscience, 2017
Conejo-Garcia, Jose R.   +2 more
openaire   +2 more sources

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

open access: yesAdvanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin   +12 more
wiley   +1 more source

BZW1 Drives Immune Evasion in Lung Adenocarcinoma via Ferroptosis Suppression

open access: yesAdvanced Science, EarlyView.
BZW1 attenuates ferroptosis by competitively binding NCOA4 and suppress ferrtinophagy‐mediated iron release. The depletion of BZW1 triggers lipid peroxidation through iron homeostasis. Extracellularly, BZW1 attenuates immunogenic cell death and reinvigorates cytotoxic T‐cell responses.
Linyao Zhao   +9 more
wiley   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy